177 related articles for article (PubMed ID: 36300467)
21. Ursodeoxycholic acid therapy in hepatobiliary disease.
Kowdley KV
Am J Med; 2000 Apr; 108(6):481-6. PubMed ID: 10781781
[TBL] [Abstract][Full Text] [Related]
22. Anticholestatic mechanisms of ursodeoxycholic acid in lipopolysaccharide-induced cholestasis.
Razori MV; Maidagan PM; Ciriaci N; Andermatten RB; Barosso IR; Martín PL; Basiglio CL; Sánchez Pozzi EJ; Ruiz ML; Roma MG
Biochem Pharmacol; 2019 Oct; 168():48-56. PubMed ID: 31202734
[TBL] [Abstract][Full Text] [Related]
23. An insight into primary biliary cholangitis and its recent advances in treatment: semi-synthetic analogs to combat ursodeoxycholic-acid resistance.
Sahu R; Mishra R; Majee C
Expert Rev Gastroenterol Hepatol; 2020 Oct; 14(10):985-998. PubMed ID: 32674617
[TBL] [Abstract][Full Text] [Related]
24. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
Stiehl A; Rudolph G; Sauer P; Theilmann L
J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
[TBL] [Abstract][Full Text] [Related]
25. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of ursodeoxycholic acid- and canrenoate-induced biliary bicarbonate secretion and the effect on glucose- and amino acid-induced cholestasis.
Omland E; Mathisen O
Scand J Gastroenterol; 1991 May; 26(5):513-22. PubMed ID: 1871544
[TBL] [Abstract][Full Text] [Related]
27. [Ursodeoxycholic acid in the treatment of cholestatic liver diseases].
Arrese M; Accatino L
Rev Med Chil; 1993 Apr; 121(4):439-46. PubMed ID: 8272619
[TBL] [Abstract][Full Text] [Related]
28. Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis.
Martinez-Gili L; Pechlivanis A; McDonald JAK; Begum S; Badrock J; Dyson JK; Jones R; Hirschfield G; Ryder SD; Sandford R; Rushbrook S; Thorburn D; Taylor-Robinson SD; Crossey MME; Marchesi JR; Mells G; Holmes E; Jones D
Gut Microbes; 2023; 15(1):2208501. PubMed ID: 37191344
[TBL] [Abstract][Full Text] [Related]
29. Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis.
Macias RI; Serrano MA; Monte MJ; Jimenez S; Hernandez B; Marin JJ
J Pharmacol Exp Ther; 2005 Feb; 312(2):751-8. PubMed ID: 15452192
[TBL] [Abstract][Full Text] [Related]
30. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
Lirussi F; Okolicsanyi L
Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
[TBL] [Abstract][Full Text] [Related]
31. Chronic cholestatic diseases.
Poupon R; Chazouillères O; Poupon RE
J Hepatol; 2000; 32(1 Suppl):129-40. PubMed ID: 10728800
[TBL] [Abstract][Full Text] [Related]
32. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.
Kotb MA
Int J Mol Sci; 2012; 13(7):8882-8914. PubMed ID: 22942741
[TBL] [Abstract][Full Text] [Related]
33. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
[TBL] [Abstract][Full Text] [Related]
34. The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis.
Kuiper EM; Hansen BE; Lesterhuis W; Robijn RJ; Thijs JC; Engels LG; Koek GH; Aparicio MN; Kerbert-Dreteler MJ; van Buuren HR;
Clin Res Hepatol Gastroenterol; 2011 Jan; 35(1):29-33. PubMed ID: 20810227
[TBL] [Abstract][Full Text] [Related]
35. [Efficacy of combined use of ursodeoxycholic acid and heptral in the treatment of primary biliary cirrhosis].
Avezov SA; Mansurova FKh
Klin Med (Mosk); 2004; 82(2):46-9. PubMed ID: 15106512
[TBL] [Abstract][Full Text] [Related]
36. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
Honda A; Ikegami T; Nakamuta M; Miyazaki T; Iwamoto J; Hirayama T; Saito Y; Takikawa H; Imawari M; Matsuzaki Y
Hepatology; 2013 May; 57(5):1931-41. PubMed ID: 22911624
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of hepatoprotective action of bile salts in liver disease.
Stiehl A; Benz C; Sauer P
Gastroenterol Clin North Am; 1999 Mar; 28(1):195-209, viii. PubMed ID: 10198785
[TBL] [Abstract][Full Text] [Related]
38. Pharmacotherapy of cholestatic liver diseases.
Paumgartner G
J Dig Dis; 2010 Jun; 11(3):119-25. PubMed ID: 20579215
[TBL] [Abstract][Full Text] [Related]
39. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases.
Trauner M; Graziadei IW
Aliment Pharmacol Ther; 1999 Aug; 13(8):979-96. PubMed ID: 10468672
[TBL] [Abstract][Full Text] [Related]
40. All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2-/- mice.
Cai SY; Mennone A; Soroka CJ; Boyer JL
J Pharmacol Exp Ther; 2014 Apr; 349(1):94-8. PubMed ID: 24492652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
